Gilead Sciences, Inc.
CH ˙ SWX ˙ US3755581036
SecurityCH:GILD / Gilead Sciences, Inc.
InstitutionVerity & Verity, LLC
Latest Disclosed Ownership272,384 shares
Latest Disclosed Value $ 37,962,109
Verity & Verity, LLC reports 0.29% increase in ownership of GILD / Gilead Sciences, Inc.

On April 15, 2026 - Verity & Verity, LLC filed a 13F-HR form disclosing ownership of 272,384 shares of Gilead Sciences, Inc. (CH:GILD) valued at $37,962,109 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 271,608 shares of Gilead Sciences, Inc.. This represents a change in shares of 0.29% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-15 2026-03-31 13F GILEAD SCIENCES COM 375558103 272,384 776 0.29 37,962 13.87 2.7877
2026-02-10 2025-12-31 13F GILEAD SCIENCES COM 375558103 271,608 909 0.34 33,337 10.95 2.5886
2025-10-21 2025-09-30 13F GILEAD SCIENCES COM 375558103 270,699 -13,079 -4.61 30,048 -4.50 2.4048
2025-08-12 2025-06-30 13F GILEAD SCIENCES COM 375558103 283,778 -43,792 -13.37 31,463 -14.28 2.7044
2025-04-16 2025-03-31 13F GILEAD SCIENCES COM 375558103 327,570 -50,532 -13.36 36,704 5.09 3.2234
2025-01-15 2024-12-31 13F GILEAD SCIENCES COM 375558103 378,102 10,771 2.93 34,925 13.40 3.1870
2024-11-07 2024-09-30 13F GILEAD SCIENCES COM 375558103 367,331 2,250 0.62 30,797 22.95 3.0173
2024-11-07 2024-06-30 13F/A-2 GILEAD SCIENCES COM 375558103 365,081 36,263 11.03 25,048 4.00 2.7296
2024-09-16 2024-06-30 13F/A-1 GILEAD SCIENCES COM 375558103 345,695 16,877 23,718 2.7101
2024-08-08 2024-06-30 13F GILEAD SCIENCES COM 375558103 357,321 46,108 24,516 2.7243
2024-11-07 2024-03-31 13F/A-2 GILEAD SCIENCES COM 375558103 328,818 -13,728 -4.01 24,086 -13.20 2.6823
2024-09-16 2024-03-31 13F/A-1 GILEAD SCIENCES COM 375558103 311,213 -31,333 22,796 2.6635
2024-04-24 2024-03-31 13F GILEAD SCIENCES COM 375558103 76,079 -259,342 9,839 1.1181
2024-11-07 2023-12-31 13F/A-1 GILEAD SCIENCES COM 375558103 342,546 1,239 0.36 27,750 8.49 3.1804
2024-02-12 2023-12-31 13F GILEAD SCIENCES COM 375558103 335,421 -5,886 27,172 3.1758
2024-11-07 2023-09-30 13F/A-1 GILEAD SCIENCES COM 375558103 341,307 4,131 1.23 25,578 -1.57 3.2041
2023-10-19 2023-09-30 13F GILEAD SCIENCES COM 375558103 333,109 -4,067 26,539 3.3786
2024-11-07 2023-06-30 13F/A-1 GILEAD SCIENCES COM 375558103 337,176 17,453 5.46 25,986 -2.04 3.1878
2023-07-10 2023-06-30 13F GILEAD SCIENCES COM 375558103 330,401 10,678 25,464 3.1849
2024-11-07 2023-03-31 13F/A-2 GILEAD SCIENCES COM 375558103 319,723 3,706 1.17 26,527 -2.22 3.3872
2024-05-02 2023-03-31 13F/A-1 GILEAD SCIENCES COM 375558103 313,048 -2,969 25,974 3.3835
2023-04-03 2023-03-31 13F GILEAD SCIENCES COM 375558103 313,048 -2,969 25,974 3.3835
2023-01-11 2022-12-31 13F GILEAD SCIENCES COM 375558103 316,017 -3,580 -1.12 27,130 37.60 3.5412
2022-10-24 2022-09-30 13F GILEAD SCIENCES COM 375558103 319,597 9,959 3.22 19,716 3.01 3.1736
2022-08-18 2022-06-30 13F GILEAD SCIENCES COM 375558103 309,638 -3,003 -0.96 19,139 2.97 2.9304
2022-05-03 2022-03-31 13F GILEAD SCIENCES COM 375558103 312,641 102,665 48.89 18,587 21.91 2.5754
2022-02-01 2021-12-31 13F GILEAD SCIENCES COM 375558103 209,976 5,053 2.47 15,246 10.37 2.1785
2021-11-04 2021-09-30 13F GILEAD SCIENCES COM 375558103 204,923 9,032 4.61 13,814 2.41 2.0673
2021-09-20 2021-06-30 13F GILEAD SCIENCES COM 375558103 195,891 0 0.00 13,489 3.38 2.1309
2021-06-21 2021-03-31 13F GILEAD SCIENCES COM 375558103 195,891 43,431 28.49 13,048 36.92 2.1112
2021-01-12 2020-12-31 13F GILEAD SCIENCES COM 375558103 152,460 19,497 14.66 9,530 12.70 1.8007
2020-10-06 2020-09-30 13F GILEAD SCIENCES COM 375558103 132,963 38,200 40.31 8,456 16.38 1.8600
2020-07-14 2020-06-30 13F GILEAD SCIENCES COM 375558103 94,763 1,992 2.15 7,266 4.76 1.7320
2020-04-09 2020-03-31 13F GILEAD SCIENCES COM 375558103 92,771 32,490 53.90 6,936 77.07 1.9546
2020-01-08 2019-12-31 13F GILEAD SCIENCES COM 375558103 60,281 35,721 145.44 3,917 157.36 0.7601
2019-10-11 2019-09-30 13F GILEAD SCIENCES COM 375558103 24,560 24,560 1,522 0.3221
2014-08-14 2014-06-30 13F GILEAD SCIENCES INC COM COM 375558103 0 -19,306 -100.00 0 -100.00
2014-05-15 2014-03-31 13F GILEAD SCIENCES INC COM COM 375558103 19,306 19,306 1,368 0.7253
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.